[Prospects and mechanistic insights into the use of recombinant human growth hormone in the treatment of pediatric inflammatory bowel disease].
Recombinant human growth hormone (rhGH) may offer a new avenue for managing growth retardation in pediatric inflammatory bowel disease, but more research is needed to confirm its efficacy and safety.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This review explores the potential use of recombinant human growth hormone (rhGH) in treating growth retardation associated with pediatric inflammatory bowel disease (PIBD). It discusses the pathogenesis of growth impairment in PIBD and evaluates recent progress and challenges in rhGH application. The review aims to provide insights for clinical management of PIBD-related growth disorders.
Abstract
Pediatric inflammatory bowel disease (PIBD) is a chronic immune-mediated inflammatory disorder of the gastrointestinal tract, with a steadily increasing global incidence. Growth retardation is one of the most common extraintestinal complications of PIBD, especially in children with Crohn's disease, severely affecting their quality of life and final adult height. The pathogenesis of this complication is complex, involving chronic intestinal inflammation, malnutrition, dysregulation of the endocrine axis, and adverse effects of glucocorticoid therapy. Current clinical management primarily focuses on controlling inflammation and optimizing nutrition, but some patients still experience persistent growth impairment. Recombinant human growth hormone (rhGH) directly promotes linear growth and its potential therapeutic value in PIBD has attracted increasing attention. This review summarizes the pathogenesis of PIBD-related growth retardation and outlines recent progress and clinical challenges in rhGH application in PIBD, aiming to provide a reference for the clinical management of PIBD-associated growth disorders.
Background
Pediatric inflammatory bowel disease (PIBD) is a chronic condition that affects the gastrointestinal tract and is increasingly prevalent worldwide. Growth retardation is a significant complication of PIBD, particularly in children with Crohn's disease, impacting their quality of life and adult height. The complexity of this issue arises from factors such as chronic inflammation, malnutrition, endocrine dysregulation, and glucocorticoid therapy. While current treatments focus on inflammation control and nutritional support, some children continue to experience growth issues, prompting interest in alternative therapies like recombinant human growth hormone (rhGH).
Methods
This paper is a review article, summarizing existing literature on the use of recombinant human growth hormone (rhGH) in pediatric inflammatory bowel disease (PIBD). It does not involve new experimental data or a specific study design. The review aims to compile and discuss the pathogenesis of PIBD-related growth retardation and the potential role of rhGH in managing this complication.
Results
Not reported in abstract.
Interpretation
The review highlights the potential of rhGH to address growth retardation in PIBD, but it does not provide new data to support its efficacy or safety. The discussion is based on existing studies, which may vary in quality and relevance. The clinical significance of rhGH in PIBD remains uncertain without robust, controlled trials demonstrating meaningful outcomes. The review underscores the need for further research to establish the therapeutic value of rhGH in this context.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- No new experimental data presented
- Relies on existing literature
- Potential biases in reviewed studies
- Lack of quantitative findings